Orthocell (ASX:OCC) submitted a medical device license application in Canada for its nerve repair product Remplir, according to a Monday Australian bourse filing.
The company expects the product to be approved in Canada in the second half of 2025.
It is planning to submit regulatory applications in Thailand in the March quarter, in the UK and the European Union in the September quarter, and in Brazil in the December quarter.
It is also evaluating Southeast Asian and Latin American markets.
It added that it expects US Food and Drug Administration approval in March or early April. Preparations for a market launch in the US are underway.
The company's shares fell past 3% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.